The round was led by Blume Ventures, with support from Schema Ventures, Vicus Ventures, Together Fund, DeVC, Medmountain Ventures, and strategic investors including Innovaccer, Memora Health, and existing customers.

The company is tackling one of healthcare’s biggest pain points which is patient phone calls. Despite digital options, 81% of patients in 2025 still use the phone to contact doctors, often facing long waits, confusing menus, or delayed responses. On the other side, understaffed front desks struggle to manage the volume, leading to frustration and burnout.

Confido’s platform removes the traditional phone tree. Its voice agents answer calls immediately, verify the caller, check insurance eligibility, and handle tasks such as referrals, refills, payments, updates, or appointment bookings. More complex issues are transferred to staff, with all interactions recorded directly into electronic health record (EHR) or practice management systems (PMS).

The need for such automation is increasing. The American Hospital Association has warned that hospitals are under severe financial strain while demand for round-the-clock access keeps growing. Many startups have entered this space in 2025, but Confido differentiates itself by offering a broader range of workflows beyond scheduling, giving providers higher efficiency and return on investment.

In less than a year, the company has scaled rapidly, serving more than one million patients today compared to just 150,000 in December 2024. Automation rates exceed 80%, with clients reporting reduced wait times, faster resolutions, and significant time savings for staff.

At Dallas Renal Group, results were immediate as 66% of patients confirmed appointments instantly on outbound calls, fewer than 6% required staff involvement, and inbound call wait times dropped to 15 seconds, saving nearly 50 staff hours in a single week. “Confido has helped make access faster, smoother, and far less stressful for everyone,” said Srinivas Danda, COO of Dallas Renal Group.

Confido’s Co-founder and CEO, Chetan Reddy, stressed the urgency of the moment. “Healthcare is at an inflection point. Labour shortages and rising patient demand mean practices can’t keep scaling front desks the way they used to. At the same time, building AI for healthcare isn’t like other industries – it requires deep empathy for both staff and patients. Our agents are designed to support people, not replace them, so patients get faster access and workers feel less stressed. That combination is what makes this moment so powerful.”

The company already operates across multiple specialities, including paediatrics, orthopaedics, nephrology, dermatology, gastroenterology, and pain medicine. Its roadmap goes beyond scheduling to include recalls, reactivation, payments, and care coordination, with speciality playbooks, audit trails, analytics, and first-call resolution metrics.

Investors are confident in Confido’s position. Sanjay Nath, partner at Blume Ventures, said: “Chetan, Vichar and the Confido team have gone incredibly deep into the trenches of the healthcare industry, having faced the pains of poor patient experience themselves – and have emerged with an offering that is transforming the way patient communication with providers is run. 

“It is clear to us that healthcare especially in the US is ripe for AI-led transformation, given the widespread administrative staff shortages, and Confido Health is well positioned to 10X the patient experience. We are very excited to lead this investment round and see a clear path to Confido becoming the market leader in this space, driven by a patient-first product ethos and close partnership with the provider ecosystem.”

Shubham Gupta, founding general partner at Together Fund, added: “Chetan, Vichar, and the Confido team have gone deeper than anyone we’ve seen in tackling the patient access problem. Their fully generative, multi-agent platform is not just a tech innovation — it’s already proving its impact in real-world provider settings by handling the communication bottlenecks that EHRs and legacy vendors have consistently failed at. 

“They are also building the most differentiated tech in this space focused on data & integrations not just voice. We’re excited to partner with them in building the market leader in AI-powered patient engagement.”

Confido Health believes that phones will remain healthcare’s most common entry point. In turning calls into efficient, human-like conversations, the company aims to become the standard infrastructure for patient communication across clinics and health systems of every size.

Today, the company announced $15 million in new funding to scale its voice AI platform, which automates high-friction insurance calls that cost provider organizations and billing companies billions of dollars every year.

The debt and equity series A round was led by SignalFire, with participation from Slow Ventures, BoxGroup, and Scrub Capital. It includes $3 million in venture debt for SuperDial to invest in R&D and go-to-market initiatives. 

In total, the company has now raised over $20 million in funding. This also marks one of the first investments from SignalFire’s new $1 billion fund focused on applied AI.

SuperDial builds AI agents that handle outbound phone calls from providers and billing companies to insurers – navigating phone trees, waiting on hold, and conducting live conversations with payer reps. 

These AI agents support tasks like benefits verification, prior authorisation, claims follow-up, and credentialing. When a call can’t be completed by an AI agent, SuperDial’s human call centre team steps in, ensuring reliable outcomes while continually improving the AI.

The platform integrates with EHRs and other systems of record to automate documentation, including writing back data gathered from calls, such as claims status updates. Customers rely on SuperDial not just to cut costs, but to unlock capacity across their revenue operations teams. Customers have reported up to 3x cost savings per call and 4x productivity gains for their existing billing teams. 

SuperDial was founded by Sam Schwager and Harrison Caruthers, who met at Stanford while studying computer science. After building a healthcare billing company that spent thousands of hours on repetitive calls to payers, they saw the opportunity to automate the problem. What started as an internal tool quickly grew into a standalone solution.

“The timing is perfect for us to tackle this problem at scale, with AI capabilities quickly maturing and the healthcare sector looking for new ways to drive efficiency by leveraging next-gen technology. Our success to date, and the incredible level of interest and excitement we’re seeing from the market, are clear signs that we’re solving a real, urgent problem,” said Sam Schwager, co-founder and CEO of SuperDial. 

Since launching at the end of 2023, the company has quickly scaled to seven figures in revenue and tens of thousands of calls per week. 

Earlier this year, SuperDial acquired MajorBoost, a voice AI company specialised in navigating complex phone trees and insurer workflows. The acquisition deepened SuperDial’s technical team and further cemented its leadership in healthcare-specific call automation.

SuperDial’s growth comes as healthcare organisations seek to cut admin costs without expanding headcount. The $150 billion U.S. RCM market still relies on manual phone calls for basic tasks – calls that can take over an hour and pull staff away from higher-impact work.

SuperDial’s customers include RCM companies and large provider organisations – including DSOs and MSOs – that manage billing in-house. Their customers rely on SuperDial to improve financial performance, reduce burnout, and unlock their teams’ capacity to focus on higher-value work. 

At West Coast Dental, SuperDial now handles over 10,000 calls per month to check claim statuses, a process that previously left nearly 70,000 claims in backlog and would have required five new hires to process. With SuperDial, the team has significantly reduced AR days and gained trustworthy, up-to-date visibility into claims.

“SuperDial isn’t just automating phone calls – they’re building the connective tissue for how the healthcare ecosystem will communicate in the future,” said Yuanling Yuan, Partner at SignalFire. 

“We believe agentic AI infrastructure is inevitable, and SuperDial is leading that shift with rapidly growing traction and a team that deeply understands the problem. This is exactly the kind of applied AI we’re excited to back.”

Looking ahead, SuperDial will deepen its EHR integrations, expand to new administrative workflows, and continue training its agents using real-world call data. 

Although healthcare never built the APIs to enable clean, system-to-system communication, SuperDial is building the next best thing: a network of AI agents that can navigate fragmented infrastructure on behalf of the organisations that rely on it. 

SuperDial believes the future of healthcare coordination will be agent-powered – where payers, providers, pharmacies, labs, and other healthcare organisations can seamlessly communicate with one another, AI-to-AI. And SuperDial will power that future.

To solve this, RISA Labs has raised a $3.5M funding round to help healthcare organizations eliminate one of the most persistent barriers to timely cancer care: prior authorization delays. 

RISA Labs has already proven that faster care is possible by dramatically reducing manual workflows and administrative burden.

The seed was led by Binny Bansal (Flipkart co-founder) with participation from Oncology Ventures, General Catalyst, z21 Ventures, ODD BIRD VC, and Ashish Gupta. The capital will accelerate deployments in the next 100 cancer centers across the country within the next two years. 

“Prior authorizations remain one of the least automated parts of our healthcare system,” said Ben Freeberg, managing partner at Oncology Ventures.

“In oncology, the stakes are higher. 70% of cancer patients experience delays in care because of prior authorization requirements. In 33% of those cases, the delay is one month—a time window that can increase the risk of death by 13% in certain cancer types. The current system isn’t just inefficient – it’s dangerous.”

RISA’s platform—Business Operating System as a Service (BOSS) – is not another automation bot or AI assistant. 

It’s a full-stack orchestration engine built for the vertical complexity of healthcare, Instead of relying on humans to push paperwork or brittle bots that break when systems change, BOSS decomposes complex workflows into micro-tasks, then delegates them to a network of intelligent agents—LLMs, digital twins, and reinforcement learners, extending across an institution’s entire software stack. 

This allows BOSS to create a parallel digital workforce, operating on behalf of teams and alongside them. A 1,000-person institution can function like a 2,000-person one overnight, with digital agents making up half the workforce.

“We’ve had Windows, we’ve had Linux, we’ve had Mac, each OS helped humans extract more from machines. But now, we’re drowning in software. There’s too much of it, and a shortage of skilled labor to operate it. Software that was supposed to get work done has become work itself,” Kshitij Jaggi, co-founder and CEO of RISA Labs adds.

“BOSS is an AI OS designed for the post-ChatGPT era : where work is no longer about learning tools, but simply expressing intent.”

At a leading US cancer center, BOSS reduced prior authorization times from 30 minutes to under five. In just a few months, it processed over $1 million in medications, freed up 80 percent of staff time, and cut administrative costs by 66 percent.

“Cancer care is time sensitive. Every delay in treatment can affect outcomes. Prior authorizations continue to slow us down. What RISA is building is not just smart technology. It removes barriers so our teams can move faster and stay focused on what matters most: caring for patients,” said Dr. Jeffrey Vacirca, CEO of New York Cancer and Blood Specialists.

Based in Silicon Valley, RISA is founded by IIT Kanpur alumni and repeat founders, Kshitij Jaggi (CEO) and Kumar Shivang (CTO) who’ve been friends for more than a decade now, who’ve previously built and scaled Urban Health. 

Their frustration with fragmented, slow, and error-prone healthcare workflows during that journey inspired the duo to take a systems-first approach, leading them to develop a foundational AI operating system that can simulate, understand, and orchestrate entire institutional workflows from end to end.

“BOSS is low-entropy system design to bring flow state in system-2 thinking for LLMs; it aims to maximise AI agents’ usefulness for critical problems like oncology operations,” said Kumar Shivang, co-founder & CTO of RISA. 

“Its orchestration layer then turns that intelligence into precise, real-time execution with integrations with systems of record like Flatiron Health’s EMR.”

RISA’s founding team first explored these concepts through research, co-authoring ‘Digital Twin Ecosystem in Oncology Clinical Operations’—an early effort to envision smarter, AI-driven cancer care workflows.

This foundational work laid the conceptual groundwork that later translated into tangible improvements in real-world oncology operations.

RISA’s platform signals a broader shift in enterprise AI. “As AI agents unbundle the $4.6 trillion services industry, RISA’s BOSS leads the way—proven in oncology and built to scale,” said Binny Bansal, co-founder of Flipkart and lead investor.

Looking ahead, RISA plans to extend across multiple nodes within the oncology ecosystem, positioning itself as the AI transformation partner for both operational and clinical workflows. 

This includes enabling coordination and intelligence across providers, life sciences organizations, and other stakeholders throughout the journey of a drug – extending the company’s long term vision to building a unified layer for AI-driven orchestration in oncology.